

Truth in Testimony Disclosure Form

In accordance with Rule XI, clause 2(g)(5)* of the *Rules of the House of Representatives*, witnesses are asked to disclose the following information. Please complete this form electronically by filling in the provided blanks.

Committee: Oversight and Accountability

Subcommittee: Full Committee

Hearing Date: July 23, 2024

Hearing Title :

The Role of Pharmacy Benefit Managers in Prescription Drug Markets Part III: Transparency and Accountability

Witness Name: Dr. Patrick Conway

Position/Title: CEO, Optum Rx

Witness Type: Governmental Non-governmental

Are you representing yourself or an organization? Self Organization

If you are representing an organization, please list what entity or entities you are representing:

Optum Rx

FOR WITNESSES APPEARING IN A NON-GOVERNMENTAL CAPACITY

Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.

Are you a fiduciary—including, but not limited to, a director, officer, advisor, or resident agent—of any organization or entity that has an interest in the subject matter of the hearing? If so, please list the name of the organization(s) or entities.

Optum Rx

Please list any federal grants or contracts (including subgrants or subcontracts) related to the hearing's subject matter that you or the organization(s) you represent have received in the past thirty-six months from the date of the hearing. Include the source and amount of each grant or contract.

Optum Rx is contracted to provide services to the Department of Veterans Affairs. In addition, our pharmacy benefit management business provides services to plans that serve Medicare and Medicaid populations, as well as federal government employees. We also contract with the federal government as a Medicare Part D Plan. Additionally, Optum Rx has affiliated pharmacies that are enrolled as Medicare or Medicaid providers.

We understand the subject matter of the hearing to be about the role of pharmacy benefit managers in prescription drug markets, with a focus on transparency and accountability. Additional information is available upon request.

Please list any contracts, grants, or payments originating with a foreign government and related to the hearing's subject that you or the organization(s) you represent have received in the past thirty-six months from the date of the hearing. Include the amount and country of origin of each contract or payment.

We have not identified any contracts with foreign governments.

Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.

- I have attached a written statement of proposed testimony.
- I have attached my curriculum vitae or biography.

* Rule XI, clause 2(g)(5), of the U.S. House of Representatives provides:

(5)(A) Each committee shall, to the greatest extent practicable, require witnesses who appear before it to submit in advance written statements of proposed testimony and to limit their initial presentations to the committee to brief summaries thereof.

(B) In the case of a witness appearing in a non-governmental capacity, a written statement of proposed testimony shall include— (i) a curriculum vitae; (ii) a disclosure of any Federal grants or contracts, or contracts, grants, or payments originating with a foreign government, received during the past 36 months by the witness or by an entity represented by the witness and related to the subject matter of the hearing; and (iii) a disclosure of whether the witness is a fiduciary (including, but not limited to, a director, officer, advisor, or resident agent) of any organization or entity that has an interest in the subject matter of the hearing.

(C) The disclosure referred to in subdivision (B)(ii) shall include— (i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government.

(D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form 24 hours before the witness appears to the extent practicable, but not later than one day after the witness appears.

False Statements Certification

Knowingly providing material false information to this committee/subcommittee, or knowingly concealing material information from this committee/subcommittee, is a crime (18 U.S.C. § 1001). This form will be made part of the hearing record.



Witness signature

July 22, 2024

Date

Patrick Conway



Dr. Patrick Conway serves as the Chief Executive Officer of Optum Rx. In this role he leads an integrated pharmacy care services organization that is making drugs more affordable and creating a better experience for consumers. Dr. Conway previously served as a leader of Optum Health, a patient-centered care organization that helps deliver better experiences for patients and care providers, improves health outcomes, lowers total cost of care, and proactively engages people in managing their health and well-being in person, in home and virtually.

Before joining Optum, Dr. Conway was president and chief executive officer of Blue Cross and Blue Shield of North Carolina. He also previously served as Deputy Administrator for Innovation and Quality at the Centers for Medicare and Medicaid Services and as director of the Center for Medicare and Medicaid Innovation and the agency's Chief Medical Officer. Before joining CMS, he oversaw clinical operations and quality improvement at Cincinnati Children's Hospital Medical Center.

Dr. Conway is a practicing pediatric hospitalist. He was elected to the National Academy of Medicine in 2014, received the President's Senior Executive Distinguished Service Award, and was a White House Fellow from 2007 to 2008. He earned his MD with high honors from Baylor College of Medicine, residency training at Boston Children's Hospital, and Master of Science in clinical epidemiology from the University of Pennsylvania.